RET Therapy for NSCLC, a New Generation of Inhibitors

Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies

Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD

Patient Advocacy Groups Fund EGFR-related Research

Mary Jo Fidler, MD

Premonitions About Lung Cancer for the Next Decade 

Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer

Tepotinib Approved for MET Exon 14 Skipping Mutated Metastatic NSCLC

IASLC GENERAL DISCLAIMER

Acute Admissions Rates for Lung Cancer Patients Up During Pandemic, Not Linked to COVID-19

Modeling Analyses Show That Expansions in Lung Cancer Screening Guidelines to Better Capture Underrepresented Populations Still Need Work

Young Investigators Awarded Grants to Study COVID-19 and Lung Cancer